Growth cycle-dependent pharmacodynamics of antichlamydial drugs

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 5, 2005, Pages 1852-1856

  Siewert, Katrin ^a   Rupp, Jan ^a   Klinger, Matthias ^a   Solbach, Werner ^a   Gieffers, Jens ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; DOXYCYCLINE; ERYTHROMYCIN; MACROLIDE; RIFAMPICIN;

ARTICLE; BACTERIAL GROWTH; CHLAMYDIA; CHLAMYDIASIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; STRAIN DIFFERENCE; SYMPTOMATOLOGY;

ANTI-BACTERIAL AGENTS; CHLAMYDIA; CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA PNEUMONIAE; ERYTHROMYCIN; HELA CELLS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON;

EID: 18244401089     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.5.1852-1856.2005     Document Type: Article

References (18)

1. Beatty, W. L., R. P. Morrison, and G. I. Byrne. 1994. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol. Rev. 58:686-699.
2. Belland, R. J., G. Zhong, D. D. Crane, D. Hogan, D. Sturdevant, J. Sharma, W. L. Beatty, and H. D. Caldwell. 2003. Genomic transcriptional profiling of the developmental cycle of Chlamydia trachomatis. Proc. Natl. Acad. Sci. USA 100:8478-8483.
3. Campbell, L. A., C. C. Kuo, and J. T. Grayston. 1998. Chlamydia pneumoniae and cardiovascular disease. Emerg. Infect. Dis. 4:571-579.
4. Dreses-Werringloer, U., I. Padubrin, B. Jurgens-Saathoff, A. P. Hudson, H. Zeidler, and L. Kohler. 2000. Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob. Agents Chemother. 44:3288-3297.
5. Dreses-Werringloer, U., I. Padubrin, L. Kohler, and A. P. Hudson. 2003. Detection of nucleotide variability in rpoB in both rifampin-sensitive and rifampin-resistant strains of Chlamydia trachomatis. Antimicrob. Agents Chemother. 47:2316-2318.
6. Gieffers, J., H. Fullgraf, J. Jahn, M. Klinger, K. Dalhoff, H. A. Katus, W. Solbach, and M. Maass. 2001. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 103:351-356.
7. Hammerschlag, M. R., and P. M. Roblin. 2000. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Int. J. Antimicrob. Agents 15:149-152.
8. Hammerschlag, M. R., K. Chirgwin, P. M. Roblin, M. Gelling, W. Dumornay, L. Mandel, P. Smith, and J. Schachter. 1992. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin. Infect. Dis. 14:178-182.
9. Kuo, C. C., L. A. Jackson, L. A. Campbell, and J. T. Grayston. 1995. Chlamydia pneumoniae (TWAR). Clin. Microbiol. Rev. 8:451-461.
10. Kutlin, A., P. M. Roblin, and M. R. Hammerschlag. 2002. Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model. J. Antimicrob. Chemother. 49: 763-767.
11. Moulding, T. S., H. Q. Le, D. Rikleen, and P. Davidson. 2004. Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin. Int. J. Tuberc. Lung Dis. 8:743-748.
12. Paavonen, J., and W. Eggert-Kruse. 1999. Chlamydia trachomatis: impact on human reproduction. Hum. Reprod. Update 5:433-447.
13. Ramirez, J. A., et al. 1996. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann. Intern. Med. 125:979-982.
14. Reddy, S. P., S. R. Yeturu, and R. Slupik. 1997. Chlamydia trachomatis in adolescents: a review. J. Pediatr. Adolesc. Gynecol. 10:59-72.
15. Schachter, J. 1983. Rifampin in chlamydial infections. Rev. Infect. Dis. Suppl. 3:S562-S564.
16. Simon, C., and W. Stille. 2000. Antibiotikatherapie in Klinik und Praxis. 10th ed. Schattauer. Stuttgart. Germany.
17. Suchland, R. J., W. M. Geisler, and W. E. Stamm. 2003. Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob. Agents Chemother. 47:636-642.
18. Wolf, K., and R. Malinverni. 1999. Effect of azithromycin plus rifampin versus that of azithromycin alone on the eradication of Chlamydia pneumoniae from lung tissue in experimental pneumonitis. Antimicrob. Agents Chemother. 43:1491-1493.